Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Compulsive hoarders feel stigmatized and are more likely to view their neighborhoods as less safe and more chaotic than ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) securities ...

A new study says common human typing errors can trip up artificial intelligence (AI) programs designed to aid health care ...